The information you provide to us for this Free Case Evaluation will be treated as strictly confidential. You will get a reply from us no later than the next business day. Submitting a case evaluation does not obligate you to hire our law firm for your lawsuit. We handle all cases on a contingency fee basis, which means that you will make no payment for our legal services until after we have succeeded in getting legal compensation for you.
NOTE: This Case Evaluation form can also be completed for situations that involve other incretin mimetic drugs which are used as diabetes medications, such as Januvia and/or Victoza -- even in there is no Byetta involved.
Diabetes drugs in the incretin mimetic class -- and their manufacturers --include:
Exenatide (Byetta, Bydureon / injection) -- Amylin, which was acquired by Bristol Myers Squibb (BMS), which co-markets with Astra-Zeneca (AZ);
Liraglutide (Victoza / injection) -- Novo Nordisk;
Sitagliptin (Januvia, Janumet, Janumet XR, Juvisync / tablets) -- Merck;
Saxagliptin (Onglyza, Kombiglyze XR / tablets) -- BMS/AZ;
Alogliptin (Nesina, Kazano, Oseni / tablets) -- Takeda; and,
Linagliptin (Tradjenta, Jentadueto / tablets) -- Boehringer Ingelheim
My Articles About Byetta
Drug Safety Regulatory Developments And The Ongoing Academic Discussions About Provocative 2013 Medical Journal Article By Peter Butler At UCLA
SUMMARY: In August we learned that both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) believe that the currently available data does not confirm recent concerns over an increased risk for pancreatic cancer with glucagonlike peptide-1 (GLP-1)-based diabetes therapies Byetta (exenatide), Januvia (sitagliptin), and Victoza (liraglutide).
And then there was the continuing debate about that controversial 2013 article by UCLA medical researcher Peter Butler, "Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors".
Earlier Byetta articles by Tom Lamb on the Drug Injury Watch blog:
Drug Injury Watch: Cancer of The Pancreas: Possible Side Effect For Diabetics Who Use Byetta, Januvia, Or Victoza?
Drug Injury Watch: Emerging Drug Safety Issue: Possible Increased Risk Of Pancreatic Cancer With Byetta, Januvia, And Victoza -- Little Is Known About Long-Term Effects
Drug Injury Watch: Warnings About Byetta Associated With Risk Of Severe Pancreatitis And Renal Failure
Drug Injury Watch: August 2008: Byetta Associated With Hemorrhagic Pancreatitis And Necrotizing Pancreatitis